Device/Diagnostics Quarterly Deal Statistics, Q1 2014
A look at financing, M&A, and alliance activity, January–March 2014
Executive Summary
Device financing dropped more than 40% to $714 million in Q1; Smith & Nephew’s $1.7 billion acquisition of ArthroCare overshadowed acquisitions. Diagnostics companies raised $568 million, a 34% increase over 2013’s final quarter; nonprofits provided assets to diagnostics firms in multiple licensing arrangements.
You may also be interested in...
ArthroCare Bid Signals Ortho Consolidation
If completed, Smith & Nephew’s acquisition of ArthroCare would help it diversify into the ENT market, but the deal may not get done as analysts speculate that competitors Stryker and J&J could step in with counteroffers. But the interest surrounding Austin, TX-based ArthroCare emphasizes the pressures being put on large joint makers to find new ways of making money in orthopedics.
Option Deal Structure Works For Myriad As It Moves To Buy Crescendo
Having watched Crescendo Bioscience gain a foothold in the market for inflammatory and autoimmune diagnostics, Myriad Genetics is now moving to acquire the company – a right it obtained via a novel strategic investment agreement in 2011.
NinePoint Medical Looks Deep For Barrett’s Esophagus
NinePoint Medical Inc. is looking to shed some insights on the mysteries of the esophagus. The venture-backed start-up launched NvisionVLE, an imaging system that can produce real-time images of the esophagus, enabling gastroenterologists to see where they need to cut when performing biopsies of tests of worrisome esophageal tissue including Barrett’s esophagus.